Elicio Therapeutics Inc (ELTX)

Sep 26, 2026

Why Is ELTX Stock Falling Today? - Stocktwits

Sep 26, 2026

Sep 25, 2026

Elicio Therapeutics Is Maintained at Buy by B. Riley Securities - Moomoo

Sep 25, 2026

Sep 24, 2026

Elicio to present new pancreatic cancer trial data at ESMO - Investing.com

Sep 24, 2026

Sep 24, 2026

Elicio to present new pancreatic cancer trial data at ESMO By Investing.com - Investing.com Nigeria

Sep 24, 2026

Sep 24, 2026

A pancreatic cancer study missed its main goal. Elicio presents new analyses Oct. 23. - Stock Titan

Sep 24, 2026

Sep 24, 2026

B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating - marketscreener.com

Sep 24, 2026

Sep 20, 2026

Elicio Therapeutics, Inc.(NasdaqCM: ELTX) dropped from S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Sep 17, 2026

Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis - kalkine.com.au

Sep 17, 2026

Sep 15, 2026

Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines - The Globe and Mail

Sep 15, 2026

Sep 15, 2026

Elicio Therapeutics (NASDAQ: ELTX) Announces 2026 Annual Meeting Date and Submission Deadlines - Kalkine Media

Sep 15, 2026

Sep 14, 2026

Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer By Investing.com - Investing.com Nigeria

Sep 14, 2026

Sep 14, 2026

Elicio Therapeutics (ELTX) sets Sept. 24 cutoff for 2026 proxy proposals - stocktitan.net

Sep 14, 2026

Sep 13, 2026

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - stocktwits.com

Sep 13, 2026

Sep 08, 2026

Ladenburg Thalmann assumes Elicio Therapeutics at Buy, target $12 - scanx.trade

Sep 08, 2026

Sep 04, 2026

Pomerantz investigates Elicio Therapeutics after Phase 2 trial failure - scanx.trade

Sep 04, 2026

Sep 04, 2026

ELTX Stock Price, Quote & Chart - ChartMill

Sep 04, 2026

Sep 03, 2026

Elicio Therapeutics closes $15M registered direct offering - scanx.trade

Sep 03, 2026

Sep 02, 2026

Director at Elicio Therapeutics (ELTX) granted 21,750 stock options - Stock Titan

Sep 02, 2026

Sep 02, 2026

Director at Elicio Therapeutics (NASDAQ: ELTX) receives 21,750 stock options - Stock Titan

Sep 02, 2026

Sep 02, 2026

Director at Elicio Therapeutics (ELTX) granted 21,750 options at $2.70 - stocktitan.net

Sep 02, 2026

Sep 02, 2026

Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities - Moomoo

Sep 02, 2026

Sep 02, 2026

Elicio Therapeutics (ELTX) director gets 21,750 options at $2.70 - Stock Titan

Sep 02, 2026

Sep 02, 2026

Director at Elicio Therapeutics (ELTX) gets 10-year stock option grant - Stock Titan

Sep 02, 2026

Sep 02, 2026

Director at Elicio Therapeutics (ELTX) gets 21,750 stock options - Stock Titan

Sep 02, 2026

Sep 02, 2026

Director at Elicio Therapeutics (ELTX) gets 21,750 options at $2.70 - stocktitan.net

Sep 02, 2026

Aug 31, 2026

Elicio Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference - Quiver Quantitative

Aug 31, 2026

Aug 31, 2026

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com

Aug 31, 2026

Aug 24, 2026

At Wells Fargo's health conference, Elicio plans one-on-one meetings - Stock Titan

Aug 24, 2026

Aug 24, 2026

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire

Aug 24, 2026

Aug 20, 2026

Schall Law investigates Elicio after Phase 2 trial failure - scanx.trade

Aug 20, 2026

Aug 20, 2026

HC Wainwright Has Bearish Forecast for ELTX Q3 Earnings - MarketBeat

Aug 20, 2026

Aug 18, 2026

Elicio (ELTX) Financial Update: Reported EPS Misses Expectations for This Review; Reaction Snapshot: Shares Move Higher 2.98% in Latest TradingShare Dilution Risk - Vinanet

Aug 18, 2026

Aug 18, 2026

Elicio Therapeutics' (ELTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Aug 18, 2026

Aug 18, 2026

Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright - Investing.com

Aug 18, 2026

Aug 18, 2026

H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $23 - Moomoo

Aug 18, 2026

Aug 17, 2026

JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Hold Rating - Moomoo

Aug 17, 2026

Aug 15, 2026

Elicio Therapeutics (ELTX) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesBanking Earnings Report - Vinanet

Aug 15, 2026

Aug 15, 2026

ELTX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentEstimate Dispersion - Vinanet

Aug 15, 2026

Aug 15, 2026

Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo

Aug 14, 2026

Aug 14, 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times

Aug 14, 2026

Aug 13, 2026

Elicio Therapeutics investigation follows Phase 2 failure - scanx.trade

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics added to Russell 2000, 3000 indexes - scanx.trade

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - MarketBeat

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Aug 13, 2026

Elicio Therapeutics, Inc. (ELTX) Free Cash Flow 2025: $37.0M outflow, up 0.5% - Stock Titan

Aug 13, 2026